Arthrosi Therapeutics clinical trials
Acquired by Swedish Orphan Biovitrum, Feb 9, 2026 · source ↗
The registry lists 10 studies whose lead sponsor is Arthrosi Therapeutics. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 14, 2026.
Before and after it joined Swedish Orphan Biovitrum
- First submitted before Arthrosi Therapeutics became part of Swedish Orphan Biovitrum
- 10
- First submitted after Arthrosi Therapeutics became part of Swedish Orphan Biovitrum
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Arthrosi Therapeutics10 studies
Something wrong with this grouping? Tell us on the Swedish Orphan Biovitrum page.
Studies
Recruiting first, then most recently updated. Showing 10 of 10. All Swedish Orphan Biovitrum studies →
- Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)CompletedNCT06439602Phase 3
Sponsor listed in the registry: Arthrosi Therapeutics · First submitted before Arthrosi Therapeutics became part of Swedish Orphan Biovitrum
- Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)CompletedNCT06846515Phase 3
Sponsor listed in the registry: Arthrosi Therapeutics · First submitted before Arthrosi Therapeutics became part of Swedish Orphan Biovitrum
- Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed PatientsActive, not recruitingNCT07116746Phase 2
Sponsor listed in the registry: Arthrosi Therapeutics · First submitted before Arthrosi Therapeutics became part of Swedish Orphan Biovitrum
- Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous GoutCompletedNCT05253833Phase 2
Sponsor listed in the registry: Arthrosi Therapeutics · First submitted before Arthrosi Therapeutics became part of Swedish Orphan Biovitrum
- Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout PatientsCompletedNCT05119686Phase 2
Sponsor listed in the registry: Arthrosi Therapeutics · First submitted before Arthrosi Therapeutics became part of Swedish Orphan Biovitrum
- Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal ImpairmentCompletedNCT04646889Phase 1
Sponsor listed in the registry: Arthrosi Therapeutics · First submitted before Arthrosi Therapeutics became part of Swedish Orphan Biovitrum
- Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout PatientsCompletedNCT04155918Phase 2
Sponsor listed in the registry: Arthrosi Therapeutics · First submitted before Arthrosi Therapeutics became part of Swedish Orphan Biovitrum
- Single-dose AME Study With [14C]AR882 in Healthy Male SubjectsCompletedNCT04508426Phase 1
Sponsor listed in the registry: Arthrosi Therapeutics · First submitted before Arthrosi Therapeutics became part of Swedish Orphan Biovitrum
- Multiple Ascending Dose Study of AR882 in Healthy Adult Male VolunteersCompletedNCT04314986Phase 1
Sponsor listed in the registry: Arthrosi Therapeutics · First submitted before Arthrosi Therapeutics became part of Swedish Orphan Biovitrum
- The Study is Designed to Evaluate Single Ascending Doses of AR882 in Healthy Adult MalesCompletedNCT04347005Phase 1
Sponsor listed in the registry: Arthrosi Therapeutics · First submitted before Arthrosi Therapeutics became part of Swedish Orphan Biovitrum